On the evening of September 6, Zhenshiming Pharmaceutical Co., Ltd. held an online media communication meeting to explain the unsuccessful sampling of tobramycin dexamethasone eye drops. The company initially determined that the product properties and particle size indicators did not meet the standards, which were highly correlated with temperature conditions and product placement methods during transportation. Zhenshiming made a special clarification. The notice from the State Drug Administration will announce that a total of 23 batches did not comply with the regulations, involving properties, particle size, and sterility items. However, according to the list annexed to the Drug Administration, it is clear that the 10 unqualified batches only did not meet the properties and particle size standards, and there were no sterility problems.

On the evening of September 6, Zhenshiming Pharmaceutical Co., Ltd. held an online media communication meeting to explain the unsuccessful sampling of tobramycin dexamethasone eye drops. The company initially determined that the product properties and particle size indicators did not meet the standards, which were highly correlated with temperature conditions and product placement methods during transportation. Zhenshiming made a special clarification. The notice from the State Drug Administration will announce that a total of 23 batches did not comply with the regulations, involving properties, particle size, and sterility items. However, according to the list annexed to the Drug Administration, it is clear that the 10 unqualified batches only did not meet the properties and particle size standards, and there were no sterility problems.